CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON.
Info & Links
CEO
John Alam
Headquarters
20 Park Plaza, Suite 424 Boston Boston, MA 02216, UNITED STATES
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.